Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 12;59(2):346.
doi: 10.3390/medicina59020346.

Oral Anticoagulation in Patients with Chronic Liver Disease

Raluca S Costache  1 , Andreea S Dragomirică  2 , Bogdan E Gheorghe  2 , Vasile D Balaban  1 , Silviu M Stanciu  1 , Mariana Jinga  1 , Daniel O Costache  3
Affiliations
Review

Oral Anticoagulation in Patients with Chronic Liver Disease

Raluca S Costache et al. Medicina (Kaunas). .

Abstract

The administration of an anticoagulant in patients with liver disease (nonalcoholic steatohepatitis-NASH, nonalcoholic fatty liver disease-NAFLD, chronic hepatitis, or cirrhosis) who have an indication (atrial fibrillation, venous thrombosis, or pulmonary embolism) is challenging because there is an imbalance between thrombosis and bleeding. There is a need to focus our attention on preventing risk factors because diabetes, obesity, dyslipidemia, smoking, and sedentary behavior are risk factors for both NASH/NAFLD and AF, and these patients require anticoagulant treatment. Patients with advanced liver disease (Child-Pugh C) were excluded from studies, so vitamin K antagonists (VKAs) are still recommended. Currently, VKAs are recommended for other conditions (antiphospholipid syndrome, mitral valve stenosis, and mechanical valve prosthesis). Amongst the patients under chronic anticoagulant treatment, especially for the elderly, bleeding as a result of the improper use of warfarin is one of the important causes of emergency admissions due to adverse reactions. DOACs are considered to be efficient and safe, with apixaban offering superior protection against stroke and a good safety profile as far as major bleeding is concerned compared to warfarin. DOACs are safe in the Child-Pugh A and B classes (except rivaroxaban), and in the Child-Pugh C class are contraindicated. Given that there are certain and reliable data for chronic kidney disease regarding the recommendations, in liver function impairment more randomized studies must be carried out, as the current data are still uncertain. In particular, DOACs have a simple administration, minimal medication interactions, a high safety and effectiveness profile, and now a reversal agent is available (for dabigatran and idarucizumab). Patients are also statistically more compliant and do not require INR monitoring.

Keywords: DOACs; VKAs; atrial fibrillation; liver disease; venous thrombosis.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Warfarin mechanism of action.
Figure 2
Figure 2
DOAC’s mechanism of action.
See this image and copyright information in PMC

References

    1. Milling T.J., Frontera J.A. Exploring Indications for the Use of Direct Oral Anticoagulants. Am. J. Manag. Care. 2017;23((Suppl. S4)):S67–S80. - PMC - PubMed
    1. Zirlik A., Bode C. Vitamin K antagonists: Relative strengths and weaknesses vs. direct oral anticoagulants for stroke prevention in patients. J. Thromb. Thrombolysis. 2017;43:365–379. doi: 10.1007/s11239-016-1446-0. - DOI - PMC - PubMed
    1. Vora P., Stewart H.M., Russell B., Asiimwe A., Brobert G. Time Trends and Treatment Pathways in Prescribing Individual Oral Anticoagulants in Patients with Nonvalvular Atrial Fibrillation: An Observational Study of More than Three Million Patients from Europe and the United States. Int. J. Clin. Pract. 2022;2022:6707985. doi: 10.1155/2022/6707985. - DOI - PMC - PubMed
    1. Virović-Jukić L., Stojsavljević-Shapeski S., Forgač J., Kukla M., Mikolašević I. Non-alcoholic fatty liver disease—A procoagulant condition? Croat. Med. J. 2021;62:25–33. doi: 10.3325/cmj.2021.62.25. - DOI - PMC - PubMed
    1. Yang Y.J., Jung M.H., Jeong S.H., Hong Y.P., Kim Y.I., An S.J. The Association between Nonalcoholic Fatty Liver Disease and Stroke: Results from the Korean Genome and Epidemiology Study (KoGES) Int. J. Environ. Res. Public Health. 2020;17:9568. doi: 10.3390/ijerph17249568. - DOI - PMC - PubMed

MeSH terms